News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
271,977 Results
Type
Article (14419)
Company Profile (282)
Press Release (257275)
Multimedia
Podcasts (57)
Webinars (9)
Section
Business (79611)
Career Advice (153)
Deals (13258)
Drug Delivery (35)
Drug Development (50524)
Employer Resources (31)
FDA (5756)
Job Trends (5147)
News (144602)
Policy (10044)
Tag
Academia (916)
Accelerated approval (4)
Adcomms (14)
Allergies (60)
Alliances (21760)
ALS (81)
Alzheimer's disease (893)
Antibody-drug conjugate (ADC) (127)
Approvals (5789)
Artificial intelligence (154)
Autoimmune disease (26)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (57)
Biotechnology (232)
Bladder cancer (67)
Brain cancer (27)
Breast cancer (206)
Cancer (1891)
Cardiovascular disease (140)
Career advice (135)
Career pathing (2)
CAR-T (145)
CDC (4)
Cell therapy (390)
Cervical cancer (9)
Clinical research (41742)
Collaboration (687)
Company closure (1)
Compensation (345)
Complete response letters (17)
COVID-19 (1050)
CRISPR (61)
C-suite (224)
Cystic fibrosis (87)
Data (2098)
Denatured (12)
Depression (47)
Diabetes (177)
Diagnostics (1315)
Digital health (3)
Diversity (3)
Diversity, equity & inclusion (9)
Drug discovery (100)
Drug pricing (32)
Drug shortages (3)
Duchenne muscular dystrophy (122)
Earnings (30357)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (49502)
Executive appointments (542)
FDA (6696)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (615)
Gene editing (123)
Generative AI (10)
Gene therapy (317)
GLP-1 (412)
Government (1101)
Grass and pollen (2)
Guidances (77)
Healthcare (6602)
HIV (12)
Huntington's disease (29)
IgA nephropathy (38)
Immunology and inflammation (114)
Immuno-oncology (5)
Indications (24)
Infectious disease (1123)
Inflammatory bowel disease (123)
Inflation Reduction Act (9)
Influenza (24)
Intellectual property (83)
Interviews (18)
IPO (7313)
IRA (11)
Job creations (865)
Job search strategy (127)
Kidney cancer (8)
Labor market (11)
Layoffs (223)
Leadership (4)
Legal (1393)
Liver cancer (34)
Longevity (8)
Lung cancer (261)
Lymphoma (139)
Machine learning (6)
Management (7)
Manufacturing (190)
MASH (78)
Medical device (2611)
Medtech (2612)
Mergers & acquisitions (6368)
Metabolic disorders (484)
Multiple sclerosis (64)
NASH (13)
Neurodegenerative disease (89)
Neuropsychiatric disorders (30)
Neuroscience (1414)
NextGen: Class of 2025 (2021)
Non-profit (855)
Now hiring (24)
Obesity (227)
Opinion (105)
Ovarian cancer (84)
Pain (52)
Pancreatic cancer (82)
Parkinson's disease (150)
Partnered (8)
Patents (173)
Patient recruitment (115)
Peanut (38)
People (25921)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14761)
Phase II (19420)
Phase III (12252)
Pipeline (1098)
Policy (66)
Postmarket research (852)
Preclinical (6264)
Press Release (30)
Prostate cancer (85)
Psychedelics (41)
Radiopharmaceuticals (220)
Rare diseases (361)
Real estate (1425)
Recruiting (12)
Regulatory (8864)
Reports (18)
Research institute (942)
Resumes & cover letters (17)
Rett syndrome (8)
RNA editing (10)
RSV (10)
Schizophrenia (75)
Series A (119)
Series B (79)
Service/supplier (1)
Sickle cell disease (49)
Special edition (13)
Spinal muscular atrophy (118)
Sponsored (13)
Startups (1984)
State (1)
Stomach cancer (5)
Supply chain (24)
Tariffs (14)
The Weekly (44)
Vaccines (244)
Venture capital (40)
Weight loss (115)
Women's health (17)
Worklife (2)
Date
Today (56)
Last 7 days (220)
Last 30 days (1076)
Last 365 days (18559)
2025 (10156)
2024 (20551)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (50)
Alaska (2)
Arizona (56)
Arkansas (5)
Asia (17597)
Australia (2978)
California (4746)
Canada (1346)
China (478)
Colorado (179)
Connecticut (175)
Delaware (137)
Europe (37786)
Florida (598)
Georgia (146)
Hawaii (1)
Idaho (16)
Illinois (284)
India (12)
Indiana (113)
Iowa (7)
Japan (122)
Kansas (66)
Kentucky (6)
Louisiana (4)
Maine (11)
Maryland (550)
Massachusetts (3811)
Michigan (86)
Minnesota (175)
Mississippi (2)
Missouri (25)
Montana (14)
Nebraska (4)
Nevada (20)
New Hampshire (14)
New Jersey (1171)
New Mexico (12)
New York (1267)
North Carolina (625)
North Dakota (6)
Northern California (2122)
Ohio (132)
Oklahoma (9)
Oregon (21)
Pennsylvania (888)
Puerto Rico (7)
Rhode Island (21)
South America (209)
South Carolina (6)
Southern California (1811)
Tennessee (29)
Texas (579)
United States (16169)
Utah (68)
Virginia (102)
Washington D.C. (36)
Washington State (412)
West Virginia (1)
Wisconsin (26)
271,977 Results for "phosplatin therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
Phosplatin Therapeutics Inc. today announced that the Company has changed its name to Promontory Therapeutics Inc.
May 5, 2022
·
2 min read
Pharm Country
Phosplatin Therapeutics Announces $37 Million Series A Financing
Phosplatin Therapeutics Inc. today announced that it has completed a $37 million Series A financing.
December 14, 2021
·
4 min read
Business
Phosplatin Therapeutics Appoints Sebastian Guth, PhD, to Board of Directors
Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the appointment of Sebastian Guth, PhD, to the company’s Board of Directors.
January 4, 2022
·
3 min read
Business
Phosplatin Therapeutics Appoints Lorenzo Galluzzi, PhD, a Pioneer in Immunogenic Cell Death Research, to Scientific Advisory Board
Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the appointment of Lorenzo Galluzzi, PhD, to the company’s Scientific Advisory Board.
March 24, 2022
·
4 min read
Business
Phosplatin Therapeutics Appoints Industry Veteran Elizabeth Tallett to Board of Directors
Phosplatin Therapeutics Inc. today announced the appointment of Elizabeth Tallett to the company’s Board of Directors.
September 29, 2021
·
3 min read
Drug Development
Phosplatin Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of PT-112 for Thymoma and Thymic Carcinoma in Collaboration with National Cancer Institute
Phosplatin Therapeutics Inc. today announced the first patient has been treated in a Phase 2 clinical trial of the company’s lead therapeutic candidate, PT-112.
April 13, 2022
·
5 min read
Pharm Country
Phosplatin Therapeutics to Present at 2021 BIO Digital
Phosplatin Therapeutics Inc. announced today that it has been selected to deliver a presentation on the development program of its lead candidate, PT-112, an immunogenic cell death (ICD) inducer, at 2021 BIO Digital, the premier biotech event.
June 10, 2021
·
4 min read
Pharm Country
Phosplatin Therapeutics Reports on PT-112’s Selective Effects and Immunogenic Cell Death in Human Prostate Cancer Cell Models at the AACR Annual Meeting 2022
Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on small molecule immunogenic therapies in oncology, reported today new non-clinical data on its lead candidate, PT-112, at the American Academy of Cancer Research (AACR) Annual Meeting 2022.
April 11, 2022
·
5 min read
Business
Phosplatin Therapeutics Collaborates with the National Cancer Institute For Phase 2 Proof of Concept Study of PT-112 in Thymoma and Thymic Carcinoma
Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health.
November 15, 2021
·
5 min read
Press Releases
NeuroEM Therapeutics(R) Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer’s Treatment
June 16, 2025
·
4 min read
1 of 27,198
Next
